Journal
BMC MUSCULOSKELETAL DISORDERS
Volume 23, Issue 1, Pages -Publisher
BMC
DOI: 10.1186/s12891-022-05396-5
Keywords
Glucagon-like peptide-1; Advanced glycation endproducts; Diabetes; Osteoporosis; Liraglutide
Categories
Funding
- National Natural Science Foundation of China [81500679]
- Natural Science Foundation of Guangdong Province, China [2017A030313519]
- Science and Technology Plan of Guangdong Province [2017A020215045]
- Science and Technology Plan of Guangzhou [202102020165]
- Guangdong Basic and Applied Basic Research Foundation [2020A1515010288, 2021A1515220101]
Ask authors/readers for more resources
GLP-1 receptor agonist liraglutide can have a beneficial effect on bone in diabetes by ameliorating the accumulation of advanced glycation endproducts (AGEs). It prevents deterioration of trabecular microarchitecture and enhances bone strength. In vitro experiments also show that GLP-1 attenuates AGEs-mediated damage in osteogenic proliferation and differentiation.
Background Diabetes-associated osteoporosis are partly caused by accumulation of advanced glycation endproducts (AGEs). Glucagon-like peptide-1 (GLP-1) has been shown to regulate bone turnover. Here we explore whether GLP-1 receptor agonist (GLP1RA) can have a beneficial effect on bone in diabetes by ameliorating AGEs. Methods In the present study, we evaluated the effects of the GLP-1 receptor agonist liraglutide, insulin and dipeptidyl peptidase-4 inhibitor saxagliptin on Zucker diabetic fatty rats. Meanwhile, we observed the effect of GLP-1 on AGEs-mediated osteoblast proliferation and differentiation and the signal pathway. Results Liraglutide prevented the deterioration of trabecular microarchitecture and enhanced bone strength. Moreover, it increased serum Alpl, Ocn and P1NP levels and decreased serum CTX. In vitro we confirmed that GLP-1 could attenuate AGEs-mediated damage in osteogenic proliferation and differentiation. Besides, GLP-1 down-regulated the ROS that caused by AGEs and the mRNA and protein expression of Rage . Conclusions Altogether, our findings suggest that GLP-1 receptor agonist promotes osteoblastogenesis and suppresses bone resorption on obese type 2 diabetic rats to a certain degree. The mechanism of these effects may be partly mediated by AGEs-RAGE-ROS pathway via the interaction with GLP-1 receptor.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available